Sacral nerve stimulation: 50 years in the making

Stephen S. Steele, MD, FRCSC

Department of Urology, Queen's University, Kingston General Hospital, Kingston, ON

See related article on page 227.

Cite as: *Can Urol Assoc J* 2012;6(4):231-2. <http://dx.doi.org/10.5489/cuaj.12194>

While it is true that sacral neuromodulation has only been approved for use in North America since 1997, the concept of sacral stimulation for “curing” voiding dysfunction first took shape almost 50 years ago. After the success of cardiac pacemakers in the 1960s, hopes were high that a number of body functions could be helped with electrical stimulation.¹ In the early 1970s, the National Institutes of Health began a comprehensive program involving numerous research centres and research disciplines. The goal was to achieve synergic voiding. Although that did not happen, intermittent voiding was achieved and the dawn of sacral nerve stimulation was upon us.^{1,2} In 1981, the University of California, San Francisco initiated the first clinical program on sacral neuromodulation (SNM) followed quickly by a large multi-centred trial from 1985 to 1992. In 1997, the Food and Drug Administration (FDA) granted Medtronic approval of the Interstim system for the treatment of urge incontinence in the United States and in 1999 the FDA approved Interstim for the treatment of symptoms of urgency-frequency syndrome and urinary retention.

Over the next 13 years, SNM has undergone a tremendous therapeutic evolution. There have been advances in treatment, including a tined lead, the use of fluoroscopic imaging and the smaller implantable pulse generators.³ The indications for SNM have also grown to include interstitial cystitis, chronic pelvic pain, fecal incontinence, constipation and neurogenic bladder.⁴⁻⁸ With these therapeutic changes researchers have searched for less invasive modalities to stimulate these sacral nerves. Posterior tibial nerve stimulation (PTNS) was first described in a small study in 1983 and was shown to inhibit bladder contractions for 2

to 3 days.⁹ This technology laid dormant until it was revived in the late 2000s when a large randomized double-blind controlled trial demonstrated it to be a safe, effective and viable treatment option for overactive bladder.¹⁰ Data for this non-invasive technology continue to accumulate with a multitude of excellent studies published over the last several years.^{11,12}

Elkelini and colleagues describe a rodent model that incorporates a novel transdermal amplitude-modulated signal (TAMS) as a non-invasive alternative to an implantable SNM to treat neurogenic detrusor overactivity.¹³ The results appear to demonstrate that the amplitude-modulated waveform is sufficient to overcome skin and tissue impedance and stimulate the sacral nerves. The authors demonstrate a decrease in the calcitonin gene-related protein (CGRP) concentration with neurostimulation and significant lowering of the cystometrogram threshold pressure ($p = 0.02$). Earlier studies using spinal cord injured rodents and SNM revealed a similar finding – lowered CGRP and elimination of bladder hyper-reflexia.¹⁴ Unfortunately for the authors, abolishment of uninhibited bladder contractions in their rodent model were not demonstrated. The results are still nonetheless, encouraging.

Perhaps, these non-invasive modalities, such as TAMS and PTNS, are the way of the future for treating voiding dysfunction. Many are skeptical that peripheral stimulation of nerves with retrograde migration of signal can actually affect various voiding patterns, despite the accumulation of robust evidence that supports this technology. Of course, these same skeptics likely didn't believe that we would be removing a prostate with the use of a robot or using lasers to obliterate stones and evaporate prostates. Whether these non-invasive technologies revolutionize the way urologists treat voiding dysfunction remains to be seen. Until then, to quote Charles Kettering: “Our imagination is the only limit to what we can hope to have in the future.”

Competing interests: None declared.

This paper has been peer-reviewed.

References

- Schmidt RA. The winding path to sacral foramen neural modulation: a historic chronology. *Int Urogynecol J* 2010;21:S431-8. <http://dx.doi.org/10.1007/s00192-010-1272-4>
- Dijkema HE, Weil EH, Janknegt RA. Initial experiences with neuromodulation as treatment for incontinence and micturition disorders in The Netherlands. *Ned Tijdschr Geneesk* 1992;136:88-90.
- Thompson, JH, Sutherland SE, Siegel SW. Sacral neuromodulation: Therapy evolution. *Indian J Urol* 2010;26:379-84. <http://dx.doi.org/10.4103/0970-1591.70576>
- Carmel R, Nouhaud FX, Leroi AM, et al. Results of sacral neuromodulation on the urinary and fecal incontinence and sexuality in 20 women suffering from double incontinence. *Prog Urol* 2012;22:424-32. Epub 2012 Feb 25. <http://dx.doi.org/10.1016/j.purol.2012.01.015>
- Govaert B, Maeda Y, Alberga J, et al. Medium-term outcome of sacral nerve modulation for constipation. *Dis Colon Rectum* 2012;55:26-31. <http://dx.doi.org/10.1097/DCR.0b013e31823898a5>
- Mowatt G, Glazener C, Jarrett M. Sacral nerve stimulation for fecal incontinence and constipation in adults: a short version Cochrane review. *Neurol Urodyn* 2008;27:155-61. <http://dx.doi.org/10.1002/nau.20565>
- Peters KM, Carey JM, Konstant DB. Sacral neuromodulation for the treatment of refractory interstitial cystitis: outcomes based on technique. *Int Urogynecol J Pelvic Floor Dysfunct* 2003;14:223-8; discussion 228. Epub 2003 Aug 26. <http://dx.doi.org/10.1007/s00192-003-1070-3>
- Sievert KD, Amend B, Gakis G, et al. Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. *Ann Neurol* 2010;67:74-84. <http://dx.doi.org/10.1002/ana.21814>
- Nakamura M, Sakurai T, Tsujimoto Y, et al. Nakamura et al. Transcutaneous electrical stimulation for the control of frequency and urge incontinence. *Hinyokika Kiyo* 1983;29:1053-9.
- Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmIT trial. *J Urol* 2010;183:1438-43. Epub 2010 Feb 20. <http://dx.doi.org/10.1016/j.juro.2009.12.036>
- MacDiarmid SA, Peters KM, Shobeiri SA, et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. *J Urol* 2010;183:234-40. <http://dx.doi.org/10.1016/j.juro.2009.08.160>
- Peters KM, Carrico DJ, Macdiarmid SA, et al. Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study. *Neurol Urodyn* 2012 Jun 5. doi: 10.1002/nau.22266. [Epub ahead of print]. <http://dx.doi.org/10.1002/nau.22266>
- Elkelini MS, Pravdiviy I, Hassouna MM. Mechanism of action of sacral nerve stimulation using a transdermal amplitude-modulated signal in a spinal cord injury rodent model. *Can Urol Assoc J* 2012;6:228-31. <http://dx.doi.org/10.5489/cuaj.11249>
- Shaker H, Wang Y, Loung D, et al. Role of C-afferent fibres in the mechanism of action of sacral nerve root neuromodulation in chronic spinal cord injury. *BJU Int* 2000;85:905-10. <http://dx.doi.org/10.1046/j.1464-410x.2000.00559.x>

Correspondence: Dr. Stephen S. Steele, Kingston General Hospital, 76 Stuart St., Kingston, ON K7L 2V7; steeles@kgk.kari.net